More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round
Author: Jennie Crabbe
ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the past four weeks totaled $85 million.
Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.
This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.